Encompass Health Q2 Earnings Beat Estimates, Stock Up 7.4%

Encompass Health Corp (EHC) reported robust second-quarter 2025 results, with adjusted EPS of $1.40 and net operating revenues of $1.5 billion, surpassing consensus estimates by 16.7% and 2.3% respectively. Performance was driven by strong net patient revenue per discharge and capacity expansion, including new hospital openings and bed additions, despite elevated operating expenses. The company also significantly raised its full-year 2025 guidance across key metrics, including net operating revenues, adjusted EBITDA, and adjusted EPS, alongside reaffirming long-term growth targets, leading to a 7.4% increase in EHC shares post-announcement.

Analysis

Encompass Health Corp. (EHC) delivered a robust second quarter for 2025, with adjusted EPS of $1.40 and revenue of $1.5 billion, surpassing consensus estimates by 16.7% and 2.3% respectively. This performance was driven by strong operational execution, evidenced by a 7.2% year-over-year increase in total discharges and a 4.2% rise in net patient revenue per discharge, both exceeding forecasts. The growth was supported by a disciplined capacity expansion strategy, which included the addition of 26 beds and a new de novo hospital. While these top-line successes are significant, they were partially tempered by a 10.4% year-over-year increase in operating expenses, primarily from higher salaries and benefits. Despite this cost pressure, the company demonstrated strong financial health, with adjusted free cash flow rallying 30.5% and long-term debt declining 1.6% from year-end 2024. Management's confidence is underscored by a substantial increase in its full-year 2025 guidance across revenues, adjusted EBITDA, and adjusted EPS, with the midpoint of the EPS outlook now suggesting 18.1% year-over-year growth. This positive outlook, combined with an increased quarterly dividend and ongoing share buybacks, prompted a 7.4% rise in the company's stock price.

Key Decisions for Investors

• The significant beat on earnings and revenue, coupled with a material increase in full-year 2025 guidance, supports a bullish outlook on EHC's operational execution and growth trajectory.
• Investors should closely monitor operating expense trends, as the 10.4% year-over-year increase in costs, particularly salaries, remains a key risk that could compress margins if not managed effectively against revenue growth.
• The combination of a dividend increase to 19 cents per share and a remaining share repurchase authorization of $433 million highlights a commitment to capital returns, which should be considered a core component of the stock's total return profile.
• Given the stock's 7.4% post-earnings rally, investors should evaluate the current valuation in light of the updated, more positive fundamental outlook before initiating or adding to a position.